HOME >> MEDICINE >> NEWS
Cost control measures limit patient and physician choice in psychotropic medications

Waltham, MA A new Brandeis University study published online in Clinical Therapeutics suggests that private health plans increasingly rely on escalating copayments to manage drug costs, as opposed to administrative controls. This makes treatment more expensive in many cases for patients, and may affect adherence to treatment, said lead author Dominic Hodgkin, associate professor at the Schneider Institute for Behavioral Health, Heller School for Social Policy and Management at Brandeis University.

In the past decade, health insurers have increasingly turned to cost controls to manage prescription drug use, but little is known about how such policies affect the use of psychotropic drugs, said Hodgkin. Between 1996 and 2001, psychotropic drug use to treat psychiatric disorders climbed from 5.9 percent to 8.1 percent of the U.S. population. Newer, better tolerated drugs account for some of the growth; however, because they are often more expensive than more established treatments, psychotropic drug spending has skyrocketed, from an estimated $3.7 billion in 1991 to $18 billion in 2001.

"This growth has raised concern among public and private health care payers, who have responded with cost-containment policies that affect the choices of patients and physicians," explained Hodgkin. The study evaluated brand antidepressants, antipsychotics and drugs used to treat attention-deficit hyperactivity disorder (ADHD).

Medicaid programs, by contrast, rely on administrative controls to manage psychotropic drug costs. These controls include prior authorization by a physician before a patient can switch to a non-preferred drug at the same copayment level. Further complicating the picture, patient non-compliance rates are high for psychotropic drugs such as antidepressants and treatments for schizophrenia.

The study evaluated a nationally representative survey of private health plans regarding mental health and substance abuse services. Most pl
'"/>

Contact: Laura Gardner
gardner@brandeis.edu
781-736-4204
Brandeis University
1-Mar-2007


Page: 1 2

Related medicine news :

1. Chromatin remodeling complex connected to DNA damage control
2. New research discovers independent brain networks control human walking
3. Study says normal but out-of-control enzyme may be culprit that signals some cells to become cancer
4. Study shows Diachrome improves blood sugar control in people with type 2 diabetes
5. Bias in statin trials, failure to control malaria, and more
6. VA tops private hospitals in infection-control study
7. Survey shows asthma not controlled in majority of patients
8. Sling surgery is more effective than Burch for bladder control in women
9. To get blood pressure under control, combination of medicines may be best
10. Animal study leading to new treatments for hemorrhagic shock and uncontrolled abdominal hemorrhage
11. Asthma study shows patients have more options to control disease

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/27/2016)... ... June 27, 2016 , ... "FCPX editors can now reveal ... Final Cut Pro X," said Christina Austin - CEO of Pixel Film Studios. ... Cut Pro X users can now reveal the media of their split screens ...
(Date:6/27/2016)... ... ... TopConsumerReviews.com recently awarded their highest five-star rating to Best Buy Eyeglasses, an ... United States and Canada wear eyeglasses. Once considered to be a purely functional part ... fashion statement. Even celebrities use glasses as a way of creating an iconic image—like ...
(Date:6/26/2016)... ... ... PawPaws brand pet supplements owned by Whole Health Supply is ... of felines. The formula is all-natural and is made from Chinese herbs that have ... Kidney Support Supplement Soft Chews are Astragalus Root Extract and Rehmannia Root Extract ...
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery services, ... Mohs Surgery and to Dr. Russell Peckham for medical and surgical dermatology. , Dr. ... skin cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was ...
(Date:6/25/2016)... CA (PRWEB) , ... June 25, 2016 , ... As ... with Magna Cum Laude and his M.D from the David Geffen School of Medicine ... and returned to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... , June 26, 2016 One of Australia,s ... announced the formation of a new biotechnology company, Noxopharm Limited [ABN ... in an IPO and to list on the ASX. ... NOX66, ready to enter a Phase 1 clinical study later this ... to address one of the biggest problems facing cancer patients - ...
(Date:6/26/2016)... Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) announced ... Act of 1976, as amended ("HSR"), with respect to ... CPXX ) expired effective June 24, 2016, ... previously announced on May 31, 2016, Jazz Pharmaceuticals and ... Jazz Pharmaceuticals has commenced a tender offer for all ...
(Date:6/26/2016)... 27, 2016  VMS Rehab Systems, Inc. ( www.vmsrehabsystemsinc.com ... whatever measures required to build a strong and stable ... currently listed on the OTC Markets-pink current trading platform. ... CEO, "We are seeing an anomaly in market trading ... only by the Company, but shareholders and market players ...
Breaking Medicine Technology:
Cached News: